[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR110986A2 - Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso - Google Patents

Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso

Info

Publication number
AR110986A2
AR110986A2 ARP180100388A ARP180100388A AR110986A2 AR 110986 A2 AR110986 A2 AR 110986A2 AR P180100388 A ARP180100388 A AR P180100388A AR P180100388 A ARP180100388 A AR P180100388A AR 110986 A2 AR110986 A2 AR 110986A2
Authority
AR
Argentina
Prior art keywords
ecteinascidine
liofilized
formulations
compositions
preparation
Prior art date
Application number
ARP180100388A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR110986(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of AR110986A2 publication Critical patent/AR110986A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicación 1: Una composición caracterizada porque comprende una ecteinascidina y un disacárido. Reivindicación 15: La formulación liofilizada de acuerdo con la reivindicación 14, caracterizada porque dicho frasco contiene una formulación que comprende: aproximadamente 0,25 mg de ET-743, aproximadamente 100 mg de sacarosa y aproximadamente 6,8 mg de fosfato, donde dichos 6,8 mg de fosfato se calculan como fosfato diácido de potasio. Reivindicación 18: Un método para preparar un vial que contiene una formulación liofilizada de una ecteinascidina, caracterizado porque comprende secar por congelación una solución a granel que comprende la ecteinascidina y un disacárido. Reivindicación 25: Uso de una solución preparada de acuerdo con la reivindicación 23 para la fabricación de un medicamento para tratar el cáncer, caracterizado porque la solución se administra mediante la infusión intravenosa.
ARP180100388A 2004-10-29 2018-02-19 Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso AR110986A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62381304P 2004-10-29 2004-10-29

Publications (1)

Publication Number Publication Date
AR110986A2 true AR110986A2 (es) 2019-05-22

Family

ID=35432682

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050104538A AR051653A1 (es) 2004-10-29 2005-10-28 Formulaciones
ARP180100388A AR110986A2 (es) 2004-10-29 2018-02-19 Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP050104538A AR051653A1 (es) 2004-10-29 2005-10-28 Formulaciones

Country Status (37)

Country Link
US (2) US8895557B2 (es)
EP (1) EP1658848B1 (es)
JP (1) JP4268163B2 (es)
KR (1) KR101188691B1 (es)
CN (2) CN102018714B (es)
AR (2) AR051653A1 (es)
AT (1) ATE368461T1 (es)
AU (1) AU2005227421B2 (es)
BR (1) BRPI0517238B1 (es)
CA (1) CA2520979C (es)
CY (1) CY1107773T1 (es)
DE (1) DE602005001833T2 (es)
DK (1) DK1658848T3 (es)
ES (1) ES2290844T3 (es)
GT (1) GT200500314A (es)
HK (1) HK1091724A1 (es)
HN (1) HN2005029978A (es)
HR (1) HRP20070374T3 (es)
IL (1) IL182776A (es)
JO (1) JO2464B1 (es)
MX (1) MXPA05011650A (es)
MY (1) MY139049A (es)
NO (1) NO328035B1 (es)
NZ (1) NZ554761A (es)
PA (1) PA8650801A1 (es)
PE (2) PE20100089A1 (es)
PL (1) PL1658848T3 (es)
PT (1) PT1658848E (es)
RS (1) RS50510B (es)
RU (1) RU2382647C2 (es)
SI (1) SI1658848T1 (es)
SV (1) SV2006002283A (es)
TW (1) TWI296523B (es)
UA (1) UA91032C2 (es)
UY (1) UY29183A1 (es)
WO (1) WO2006046079A1 (es)
ZA (1) ZA200703450B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
ATE495793T1 (de) * 2000-11-06 2011-02-15 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
CA2462502A1 (en) * 2001-10-19 2003-05-15 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
NZ552607A (en) * 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
UA87877C2 (en) * 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
ME02395B (me) 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
ES2930140T3 (es) * 2011-04-28 2022-12-07 Oncopeptides Ab Preparación liofilizada de dipéptidos citotóxicos
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN106880592B (zh) * 2015-12-15 2021-04-06 江苏恒瑞医药股份有限公司 一种曲贝替定的纳米乳及其制备方法
US10610529B2 (en) * 2016-02-04 2020-04-07 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20210169873A1 (en) * 2019-10-21 2021-06-10 RK Pharma Solutions LLC Storage-stable ready-to-use injectable formulations of Trabectedin
KR20220119618A (ko) * 2019-11-21 2022-08-30 파르마 마르, 에스.에이. 루비넥테딘 제형으로 소세포폐암을 치료하는 방법
SI4041194T1 (sl) 2020-04-15 2024-10-30 Ever Valinject Gmbh Sestava, obsegajoča trabektedin in aminokislino
US20230226051A1 (en) * 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition
WO2024131887A1 (zh) * 2022-12-22 2024-06-27 博瑞生物医药（苏州）股份有限公司 一种含卢比替定的药物组合物及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO1987007610A2 (en) * 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) * 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AU7589898A (en) 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
IL138856A0 (en) 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
JP4583598B2 (ja) 1998-05-11 2010-11-17 ファルマ・マール・ソシエダード・アノニマ エクテイナシジン７４３の代謝産物
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
BRPI0110024B8 (pt) 2000-04-12 2021-05-25 Pharma Mar Sa derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
JP2004506430A (ja) * 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
AU2002210749B2 (en) * 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
CA2447553A1 (en) 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
ATE495793T1 (de) 2000-11-06 2011-02-15 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
HUP0302567A2 (hu) * 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
CZ20032266A3 (cs) 2001-03-06 2004-02-18 Bristol-Myers Squibb Company Dávkovací formy pro ošetřování nádorů
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
CA2462502A1 (en) * 2001-10-19 2003-05-15 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
NZ552607A (en) * 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
UA87877C2 (en) 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
AU2006318226A1 (en) * 2005-11-25 2007-05-31 Pharma Mar, S.A. Sociedad Unipersonal Use of PARP-1 inhibitors
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
MXPA05011650A (es) 2006-05-17
US20150094313A1 (en) 2015-04-02
PE20100089A1 (es) 2010-03-01
RS50510B (sr) 2010-03-02
PE20060925A1 (es) 2006-10-23
GT200500314A (es) 2007-03-22
AU2005227421B2 (en) 2007-06-28
JP4268163B2 (ja) 2009-05-27
BRPI0517238B1 (pt) 2021-11-09
PA8650801A1 (es) 2006-09-22
US20060094687A1 (en) 2006-05-04
KR101188691B1 (ko) 2012-10-09
TWI296523B (en) 2008-05-11
ATE368461T1 (de) 2007-08-15
AU2005227421A1 (en) 2006-05-18
TW200621256A (en) 2006-07-01
HN2005029978A (es) 2009-10-27
KR20070091121A (ko) 2007-09-07
NO328035B1 (no) 2009-11-10
MY139049A (en) 2009-08-28
RU2007119724A (ru) 2008-12-10
NZ554761A (en) 2010-01-29
IL182776A0 (en) 2007-08-19
ES2290844T3 (es) 2008-02-16
HK1091724A1 (en) 2007-01-26
EP1658848B1 (en) 2007-08-01
NO20072713L (no) 2007-07-19
JO2464B1 (en) 2009-01-20
CN102018714B (zh) 2014-01-08
JP2006124393A (ja) 2006-05-18
AR051653A1 (es) 2007-01-31
DE602005001833T2 (de) 2008-04-17
HRP20070374T3 (en) 2007-10-31
ZA200703450B (en) 2008-09-25
DK1658848T3 (da) 2007-11-26
CY1107773T1 (el) 2013-06-19
PL1658848T3 (pl) 2007-12-31
EP1658848A1 (en) 2006-05-24
UA91032C2 (en) 2010-06-25
CA2520979A1 (en) 2006-02-15
US10322183B2 (en) 2019-06-18
SI1658848T1 (sl) 2007-12-31
DE602005001833D1 (de) 2007-09-13
SV2006002283A (es) 2006-07-20
BRPI0517238A (pt) 2008-10-07
US8895557B2 (en) 2014-11-25
RU2382647C2 (ru) 2010-02-27
WO2006046079A1 (en) 2006-05-04
CN102018714A (zh) 2011-04-20
PT1658848E (pt) 2007-11-05
CN1823794A (zh) 2006-08-30
CA2520979C (en) 2009-03-24
UY29183A1 (es) 2006-05-31
IL182776A (en) 2010-06-30

Similar Documents

Publication Publication Date Title
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
PE20091184A1 (es) Formas de dosificacion farmaceutica
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AR033671A1 (es) Composicion farmaceutica acuosa del tipo de gel para administracion subcutanea, procedimiento para su preparacion y el uso de dicha composicion para la preparacion de un medicamento
BRPI0513508A (pt) conjugados de insulina-oligÈmero, formulações e usos desses
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
RU2013120311A (ru) Терапевтическое применение агониста tlr и комбинированная терапия
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
TN2009000124A1 (en) Injectable depot composition and its process of preparation
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
US20180256509A1 (en) Nanoparticle Compositions and Methods Thereof to Restore Vascular Integrity
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
EA200501203A1 (ru) Жидкие фармацевтические композиции палоносетрона
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
AR098745A2 (es) Composición, kit y uso de compuestos quimioterapéuticos
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
BRPI0519280A2 (pt) composto, composiÇço farmacÊutica e uso de um composto
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
MX2008001532A (es) Composicion farmaceutica que contiene indometacina y/o acemetacina.
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo

Legal Events

Date Code Title Description
FC Refusal